The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4+Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited Settings
Open accessAbstract
BACKGROUND: Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy. METHODS: There were 609 ART-naive adults with AIDS who started ART in Kampala, Uganda, and who had a serum CRAG prospectively measured during 2004-2006. The number needed to test and treat with a positive CRAG was assessed for > or = 30-month outcomes. RESULTS: In the overall cohort, 50 persons (8.2%) were serum CRAG positive when starting ART. Of 295 people with a CD4(+) cell count < or = 100 cells/microL and without prior CM, 26 (8.8%; 95% confidence interval [CI], 5.8%-12.6%) were CRAG positive, of whom 21 were promptly treated with fluconazole (200-400 mg) for 2-4 weeks. Clinical CM developed in 3 fluconazole-treated persons, and 30-month survival was 71% (95% CI, 48%-89%). In the 5 CRAG-positive persons with a CD4(+) cell count < or = 100 cells/microL treated with ART but not fluconazole, all died within 2 months of ART initiation. The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9-17.1) at costs of $190 (95% CI, $132-$287). The number needed to test and treat to save 1 life is 15.9 (95% CI, 11.1-24.0) at costs of $266 (95% CI, $185-$402). The cost per disability-adjusted life year saved is $21 (95% CI, $15-$32). CONCLUSIONS: Integrating CRAG screening into HIV care, specifically targeting people with severe immunosuppression (CD4(+) cell count < or = 100 cells/microL) should be implemented in treatment programs in resource-limited settings. ART alone is insufficient treatment for CRAG-positive persons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults
French, N., Gray, K., Watera, C., Nakiyingi, J., Lugada, E., Moore, M., Lalloo, D., Whitworth, J. A. G., & Gilks, C. F. (2002) · AIDS · doi:10.1097/00002030-200205030-00009 · Cited by 417
Jarvis, J. N., Lawn, S. D., Vogt, M., Bangani, N., Wood, R., & Harrison, T. S. (2009) · Clinical Infectious Diseases · doi:10.1086/597262 · Cited by 318
Kambugu, A., Meya, D. B., Rhein, J., O’Brien, M., Janoff, E. N., Ronald, A. R., Kamya, M. R., Mayanja‐Kizza, H., Sande, M. A., Bohjanen, P. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587667 · Cited by 300
Self-citationBicanic, T., Meintjes, G., Wood, R., Hayes, M., Rebe, K., Bekker, L.-G., & Harrison, T. (2007) · Clinical Infectious Diseases · doi:10.1086/518607 · Cited by 271
HIV-associated cryptococcal meningitis
Jarvis, J. N., & Harrison, T. S. (2007) · AIDS · doi:10.1097/qad.0b013e3282a4a64d · Cited by 252
Liechty, C. A., Solberg, P., Were, W., Ekwaru, J. P., Ransom, R. L., Weidle, P. J., Downing, R., Coutinho, A., & Mermin, J. (2007) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2007.01874.x · Cited by 207
Longley, N., Muzoora, C., Taseera, K., Mwesigye, J., Rwebembera, J., Chakera, A., Wall, E., Andia, I., Jaffar, S., & Harrison, T. S. (2008) · Clinical Infectious Diseases · doi:10.1086/593194 · Cited by 202
Jenny‐Avital, E. R., & Abadi, M. (2002) · Clinical Infectious Diseases · doi:10.1086/344467 · Cited by 185
Bicanic, T., Meintjes, G., Rebe, K., Williams, A., Loyse, A., Wood, R., Hayes, M., Jaffar, S., & Harrison, T. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181a56f2e · Cited by 175
Micol, R., Lortholary, O., Sar, B., Laureillard, D., Ngeth, C., Dousset, J., Chanroeun, H., Ferradini, L., Guerin, P. J., Dromer, F., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31811ed32c · Cited by 144
Lawn, S. D., Bekker, L., Myer, L., Orrell, C., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000191232.16111.f9 · Cited by 130
When to Start Antiretroviral Therapy in Resource-Limited Settings
Walensky, R. P., Wolf, L. L., Wood, R., Fofana, M. O., Freedberg, K. A., Martinson, N. A., Paltiel, A. D., Anglaret, X., Weinstein, M. C., Losina, E., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-3-200908040-00138 · Cited by 129
Mayanja‐Kizza, H., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K., Izumi, T., Ococi-Jungala, Augustine, K., Mugerwa, R. D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516372 · Cited by 128
Castelnuovo, B., Manabe, Y. C., Kiragga, A. N., Kamya, M. R., Easterbrook, P., & Kambugu, A. (2009) · Clinical Infectious Diseases · doi:10.1086/605500 · Cited by 126
Self-citationPongsai, P., Atamasirikul, K., & D, S. S. M. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.03.015 · Cited by 108
Desmet, P., Kayembe, K. D., & Vroey, C. D. (1989) · AIDS · doi:10.1097/00002030-198902000-00004 · Cited by 97
Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania
Kisenge, P. R., Hawkins, A. T., Maro, V. P., Mchele, J. P., Swai, N., Müeller, A., & Houpt, E. R. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-39 · Cited by 59
Treatments of AIDS-related Kaposi's sarcoma
Aversa, S. M. L., Cattelan, A. M., Salvagno, L., Crivellari, G., Banna, G. L., Trevenzoli, M., Chiarion‐Sileni, V., & Monfardini, S. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.009 · Cited by 55
Systematic Screening of Cryptococcal Antigenemia in HIV-Positive Adults in Uganda
Tassie, J.-M., Pepper, L. J., Fogg, C., Biraro, S., Mayanja, B., Andia, I., Paugam, A., Priotto, G., & Legros, D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200307010-00019 · Cited by 41
Singh, N., Barnish, M. J., Berman, S., Bender, B. S., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.6.1282 · Cited by 40
Wright, P., & Inverarity, D. (2007) · PubMed · Cited by 9
Cited by
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861
Self-citationMaziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis
Rajasingham, R., Govender, N. P., Jordan, A., Loyse, A., Shroufi, A., Denning, D. W., Meya, D. B., Chiller, T. M., & Boulware, D. R. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00499-6 · Cited by 587
Self-citationLimper, A. H., Adenis, A., Le, T., & Harrison, T. S. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30303-1 · Cited by 472
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, P. R., Jarvis, J. N., Panackal, A. A., Fisher, M. C., Molloy, S. F., Loyse, A., & Harrison, T. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.167 · Cited by 480
Metadata
- Authors
- Meya, D. B., Manabe, Y. C., Castelnuovo, B., Cook, B. A., Elbireer, A. M., Kambugu, A., Kamya, M. R., Bohjanen, P. R., & Boulware, D. R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-08-15
- Volume
- 51
- Issue
- 4
- Pages
- 448-455
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2127250507
- Cited by
- 296
- References
- 23
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.